atai Life Sciences Announces the Launch of PsyProtix, to Develop a Precision Psychiatry Approach for Treatment-Resistant Depression (TRD)

NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix is a precision psychiatry company focused on developing therapeutics … Continue reading atai Life Sciences Announces the Launch of PsyProtix, to Develop a Precision Psychiatry Approach for Treatment-Resistant Depression (TRD)